Trastuzumab-induced corneal ulceration: successful no-drug treatment of a “blind” side effect in a case report

por Orlandi, A., Fasciani, R., Cassano, A., Agresta, A., Calegari, M. A., Caporossi, A., Barone, C.
Publicado 2015

Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer.

por Landriscina, M., Cassano, A., Ratto, C., Longo, R., Ippoliti, M., Palazzotti, B., Crucitti, F., Barone, C.
Publicado 1998

Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases

por Barone, C, Nuzzo, G, Cassano, A, Basso, M, Schinzari, G, Giuliante, F, D'Argento, E, Trigila, N, Astone, A, Pozzo, C
Publicado 2007

Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial

por Barone, C, Landriscina, M, Quirino, M, Basso, M, Pozzo, C, Schinzari, G, Leonardo, G Di, D'Argento, E, Trigila, N, Cassano, A
Publicado 2007

ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas

por Orlandi, A., Di Salvatore, M., Bagalà, C., Basso, M., Strippoli, A., Plastino, F., Calegari, M.A., Cassano, A., Astone, A., Barone, C.
Publicado 2015

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients

por Basso, M, Strippoli, A, Orlandi, A, Martini, M, Calegari, M A, Schinzari, G, Di Salvatore, M, Cenci, T, Cassano, A, Larocca, L M, Barone, C
Publicado 2013

A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation

por Calegari, M A, Inno, A, Monterisi, S, Orlandi, A, Santini, D, Basso, M, Cassano, A, Martini, M, Cenci, T, de Pascalis, I, Camarda, F, Barbaro, B, Larocca, L M, Gori, S, Tonini, G, Barone, C
Publicado 2017